Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -98.94% is 23% above its 5-year average of -128.29%, near the high end of its 5-year range (-469.27%–-15.43%).
As of the fiscal period ended Wednesday, December 31, 2025. 73.02% below its 12-month average of -57.19%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -84.38%.
RETURN ON ASSETS (ROA)
-98.94%
RETURN ON ASSETS (ROA) AVG TTM
-57.19%
RETURN ON ASSETS (ROA) AVG 3Y
-57.75%
RETURN ON ASSETS (ROA) AVG 5Y
-128.29%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-73.02%
CURRENT VS 3Y AVG
-71.33%
CURRENT VS 5Y AVG
+22.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-206.89%
vs the sector median at left
Connect Biopharma Holdings Limited
Market Cap
$57.01M
Return on Assets (ROA)
-98.94%
TTM Avg
-57.19%
3Y Avg
-57.75%
5Y Avg
-128.29%
Market Cap
$57.61M
Return on Assets (ROA)
-56.24%
TTM Avg
-59.70%
3Y Avg
-30.02%
5Y Avg
-37.67%
Market Cap
$57.76M
Return on Assets (ROA)
-37.05%
TTM Avg
-34.36%
3Y Avg
-41.63%
5Y Avg
-37.74%
Market Cap
$56.02M
Return on Assets (ROA)
-42.67%
TTM Avg
-85.33%
3Y Avg
-379.34%
5Y Avg
-281.82%
Market Cap
$58.06M
Return on Assets (ROA)
-44.47%
TTM Avg
-42.63%
3Y Avg
-230.85%
5Y Avg
-167.04%
Market Cap
$58.29M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
Market Cap
$58.43M
Return on Assets (ROA)
-66.80%
TTM Avg
-56.95%
3Y Avg
-50.95%
5Y Avg
-40.99%
Market Cap
$58.44M
Return on Assets (ROA)
-382.32%
TTM Avg
-98.02%
3Y Avg
-80.35%
5Y Avg
-65.77%
Market Cap
$55.25M
Return on Assets (ROA)
-48.49%
TTM Avg
-50.18%
3Y Avg
-39.97%
5Y Avg
-38.29%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Connect Biopharma Holdings Limited (CNTB) | $57.01M | -98.94% | -57.19% | -57.75% | -128.29% |
| Talphera, Inc. (TLPH)vs › | $57.61M | -56.24% | -59.70% | -30.02% | -37.67% |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | -37.05% | -34.36% | -41.63% | -37.74% |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | -42.67% | -85.33% | -379.34% | -281.82% |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | -44.47% | -42.63% | -230.85% | -167.04% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | -118.15% | -138.13% | -224.99% | -221.92% |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | -66.80% | -56.95% | -50.95% | -40.99% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | -382.32% | -98.02% | -80.35% | -65.77% |
| Aldeyra The (ALDX)vs › | $55.25M | -48.49% | -50.18% | -39.97% | -38.29% |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | -14.15% | -52.30% | -73.34% | -79.94% |
ROA
-98.9%
ROE
-132.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -98.94% |
| 2024-12-31 | -15.43% |
| 2023-12-31 | -48.76% |
| 2022-12-31 | -67.86% |
| 2021-12-31 | -69.49% |
| 2020-12-31 | -469.27% |
| 2019-12-31 | -316.66% |
| 2018-12-31 | 0.00% |
